AlphaCentric Advisors LLC Invests $2.36 Million in Indivior PLC (NASDAQ:INDV)

AlphaCentric Advisors LLC bought a new position in shares of Indivior PLC (NASDAQ:INDV - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 242,500 shares of the company's stock, valued at approximately $2,364,000. Indivior makes up approximately 1.8% of AlphaCentric Advisors LLC's portfolio, making the stock its 9th largest position. AlphaCentric Advisors LLC owned about 0.18% of Indivior at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. M&G Plc acquired a new position in shares of Indivior in the first quarter valued at approximately $2,518,000. VELA Investment Management LLC boosted its stake in shares of Indivior by 722.9% in the 3rd quarter. VELA Investment Management LLC now owns 123,435 shares of the company's stock valued at $1,212,000 after buying an additional 108,435 shares during the period. Janus Henderson Group PLC grew its position in shares of Indivior by 14.2% during the first quarter. Janus Henderson Group PLC now owns 440,121 shares of the company's stock worth $9,424,000 after buying an additional 54,750 shares in the last quarter. Vanguard Group Inc. lifted its stake in Indivior by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company's stock worth $90,081,000 after acquiring an additional 52,836 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new stake in shares of Indivior in the 1st quarter valued at $1,523,000. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Stock Performance

Indivior stock traded up $0.02 during midday trading on Tuesday, hitting $9.20. 390,859 shares of the company's stock were exchanged, compared to its average volume of 463,753. The firm's 50 day simple moving average is $9.75 and its 200 day simple moving average is $13.28. Indivior PLC has a 12-month low of $7.33 and a 12-month high of $23.22. The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.65 and a current ratio of 0.83. The stock has a market cap of $1.27 billion, a price-to-earnings ratio of -229.44 and a beta of 0.70.

Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings results on Thursday, October 24th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.15. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. The firm had revenue of $307.00 million for the quarter, compared to analysts' expectations of $302.25 million. Equities research analysts predict that Indivior PLC will post 1.66 EPS for the current year.

Analysts Set New Price Targets

INDV has been the subject of a number of recent analyst reports. Piper Sandler reaffirmed an "overweight" rating and set a $16.00 price target (up from $15.00) on shares of Indivior in a report on Friday, October 25th. Craig Hallum reduced their price objective on shares of Indivior from $20.00 to $16.00 and set a "buy" rating for the company in a research report on Friday, October 11th.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.